MedTrace Logo

China Betaferon Adherence, Coping and Nurse Support Study

NCT01436838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2016-09-05

No results posted yet for this study

Summary

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

Conditions

  • Multiple Sclerosis, Chronic Progressive

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-09-30
Completion
2015-12-31

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436838 on ClinicalTrials.gov